Cytokinetics (CYTK) Stock Price, Quote & News

Latest News on CYTK

May 29, 2025, 4:00 PM EDT - 5 days ago

Cytokinetics to Participate in the Jefferies Global Healthcare Conference

May 20, 2025, 10:00 AM EDT - 14 days ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Cytokinetics, Incorporated (CYTK) And Encourages Shareholders to Reach Out

May 19, 2025, 10:00 AM EDT - 15 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cytokinetics, Incorporated (CYTK) and Encourages Shareholders to Learn More About the Investigation

May 18, 2025, 10:00 AM EDT - 16 days ago

Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

May 18, 2025, 8:00 AM EDT - 16 days ago

Cytokinetics Presents Additional Data Related to Aficamten at the European Society of Cardiology Heart Failure 2025 Congress

May 16, 2025, 4:00 PM EDT - 18 days ago

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 16, 2025, 10:00 AM EDT - 18 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Shareholders to Inquire about Securities Investigation

May 15, 2025, 10:00 AM EDT - 19 days ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Investors to Connect

May 15, 2025, 7:30 AM EDT - 19 days ago

Cytokinetics to Host Symposium on Contemporary Landscapes in Muscle Biology

May 14, 2025, 10:00 AM EDT - 20 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Stockholders to Inquire about Securities Investigation

May 13, 2025, 4:06 PM EDT - 21 days ago

Cytokinetics: PDUFA Date Extension For Aficamten Is Not At All Earth Shattering

May 13, 2025, 10:00 AM EDT - 21 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cytokinetics, Incorporated (CYTK) and Encourages Investors to Learn More About the Investigation

May 13, 2025, 7:45 AM EDT - 21 days ago

Cytokinetics' heart disease drug meets main goal in late-stage study

May 13, 2025, 7:30 AM EDT - 21 days ago

Cytokinetics Announces Positive Topline Results From MAPLE-HCM

May 12, 2025, 10:00 AM EDT - 22 days ago

Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 9, 2025, 10:00 AM EDT - 25 days ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Stockholders to Connect

May 8, 2025, 4:00 PM EDT - 26 days ago

Cytokinetics Announces Four Upcoming Presentations at the European Society Of Cardiology Heart Failure 2025 Congress

May 8, 2025, 10:00 AM EDT - 26 days ago

Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

May 7, 2025, 4:00 PM EDT - 27 days ago

Cytokinetics to Hold Annual Meeting of Stockholders

May 7, 2025, 11:29 AM EDT - 27 days ago

Cytokinetics: Strong Buy As FDA's 3-Month Delay Doesn't Derail Aficamten's Approval Outlook

May 7, 2025, 10:00 AM EDT - 27 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cytokinetics, Incorporated (CYTK) and Encourages Stockholders to Learn More About the Investigation

May 7, 2025, 1:56 AM EDT - 4 weeks ago

Cytokinetics, Incorporated (CYTK) Q1 2025 Earnings Call Transcript

May 6, 2025, 6:12 PM EDT - 4 weeks ago

CYTK Investors Have Opportunity to Join Cytokinetics, Incorporated Fraud Investigation with the Schall Law Firm

May 6, 2025, 4:00 PM EDT - 4 weeks ago

Cytokinetics Reports First Quarter 2025 Financial Results and Provides Business Update

May 6, 2025, 10:00 AM EDT - 4 weeks ago

Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Investors to Inquire about Securities Investigation

May 5, 2025, 1:45 PM EDT - 4 weeks ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Cytokinetics, Incorporated (CYTK) And Encourages Investors to Reach Out

May 2, 2025, 3:37 PM EDT - 4 weeks ago

FDA Pushes Potential Approval For Cytokinetics' Experimental Heart Drug By Three Months

May 2, 2025, 11:45 AM EDT - 4 weeks ago

Cytokinetics, Incorporated Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - CYTK

May 1, 2025, 4:15 PM EDT - 4 weeks ago

Cytokinetics Announces New PDUFA Date for Aficamten in Obstructive Hypertrophic Cardiomyopathy

Apr 30, 2025, 4:00 PM EDT - 4 weeks ago

Cytokinetics to Participate in May Investor Conferences

Apr 22, 2025, 4:00 PM EDT - 6 weeks ago

Cytokinetics to Announce First Quarter Results on May 6, 2025

Mar 31, 2025, 4:00 PM EDT - 2 months ago

Cytokinetics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 20, 2025, 7:30 AM EDT - 2 months ago

Market Cap	3.70B
Revenue (ttm)	18.47M
Net Income (ttm)	-589.53M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-3,191.82%
Debt to Equity Ratio	-0.39

Volume	1,258,100
Avg Vol	2,299,734
Day's Range	N/A - N/A
Shares Out	119.43M
Stochastic %K	43%
Beta	0.81
Analysts	Strong Sell
Price Target	$72.75